Meredith Fensom

@Meredith_Fensom

Biotech enthusiast, trade & regulatory policy wonk; Florida native & Washington, DC dweller. Views are my own.

Washington, DC
Vrijeme pridruživanja: studeni 2013.

Tweetovi

Blokirali ste korisnika/cu @Meredith_Fensom

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Meredith_Fensom

  1. proslijedio/la je Tweet
    4. velj

    Today is . Join as we strive to find new therapies for difficult-to-treat cancers. Together, we can advance medicine with precision in the pursuit of new treatment options.

    Poništi
  2. proslijedio/la je Tweet

    “Thank you for saving my life." Tomas Dahl (pictured left) was diagnosed with tonsil cancer and told there was no cure. But after trying the cancer therapy pioneered by the 2018 Medicine Laureates (centre and right), he emerged cancer-free.

    Poništi
  3. proslijedio/la je Tweet
    3. velj

    Congratulations to the team and our new shareholders for the start of a new chapter. We look forward to continuing to live by our brand promise to advance medicine with precision.

    Poništi
  4. proslijedio/la je Tweet
    3. velj
    Poništi
  5. proslijedio/la je Tweet
    3. velj

    Welcome investors to . This new site provides the latest updates on and our progress as we advance medicine with precision.

    Poništi
  6. proslijedio/la je Tweet
    31. sij

    ICER finalizes 2020-2023 Value Assessment Framework. Updates place stronger emphasis on real-world evidence, deliberation over broader contextual considerations, and patient engagement before/during/after each value assessment.

    Poništi
  7. proslijedio/la je Tweet
    29. sij

    Just published: results of Cornell University field studies with Oxitec's solution for diamondback moth, a widely insecticide-resistant pest damaging important food crops around the world

    Poništi
  8. proslijedio/la je Tweet
    29. sij

    Enjoying the opening remarks from Marty Rosendale at the Annual Leadership Dinner.

    Poništi
  9. proslijedio/la je Tweet
    29. sij

    We are excited to start our luncheon on Emerging Opportunities in Addressing Healthcare Costs: The Role of Biosimilars with Robert Popovian, Vice President, US Government Relations with

    Poništi
  10. proslijedio/la je Tweet
    29. sij

    Thank you for hosting the Annual Annapolis Day & Leadership Dinner. enjoyed speaking with General Assembly Members about delivering innovative solutions to pressing healthcare challenges.

    Poništi
  11. proslijedio/la je Tweet
    29. sij

    Maryland’s innovation economy creates life-changing treatments for patients around the country. And the cutting-edge life sciences firms that call MD home create thousands of high paying jobs. Our members are in Annapolis today urging lawmakers to protect innovation.

    Poništi
  12. proslijedio/la je Tweet
    15. sij

    - Precigen provides 2020 preclinical milestones during - an exciting year ahead for the company!

    Poništi
  13. proslijedio/la je Tweet
    15. sij

    - Precigen provides 2020 clinical milestones during

    Poništi
  14. proslijedio/la je Tweet
    15. sij

    - Check out Precigen's latest clinical and partnered pipeline presented at

    Poništi
  15. proslijedio/la je Tweet
    15. sij

    - Check out Precigen's preclinical pipeline presented at

    Poništi
  16. proslijedio/la je Tweet
    13. sij

    Join Dr. Helen Sabzevari, President and CEO of Precigen, at for her presentation on Precigen’s progress and a 2020 look ahead.

    Poništi
  17. proslijedio/la je Tweet
    10. sij

    Today, ARM released a report by Marwood Group illustrating the potential for & to provide cost savings. In , A, and multiple myeloma, this represents an aggregate cost savings of $33B+ over ten years:

    Poništi
  18. proslijedio/la je Tweet
    9. sij

    Triple-Gene to highlight advantages of its multigenic approach for treatment of at on January 15th, 2020 at 11:30AM PT at the Hilton San Francisco Union Square. Read more here:

    Poništi
  19. proslijedio/la je Tweet
    7. sij

    Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.

    Poništi
  20. proslijedio/la je Tweet
    6. sij

    receives first regulatory designation for PRGN-3006 UltraCAR-T

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·